Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
This article was originally published in The Pink Sheet Daily
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.
You may also be interested in...
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.
Biogen CEO George Scangos spoke about the unnecessary overlap of the company's corporate venture fund and its business development unit at Windhover's recent Pharmaceutical Strategic Alliance conference.
Still transforming their organizations to deal with the waning influence of the individual prescriber, pharma commercial leaders now face a new challenge: the growth of the corporate model of care, as large numbers of US physicians exchange the independence of physician-ownership for the predictability of working as employees in larger organizations. Corporate models of care, characterized by more centralized decision making, add a new dimension of customer complexity in an already tough environment.